The authors would like to make the following corrections to this published paper [1].
In the original publication [1], there was a mistake in the first column of Table 1, published as “INO-4500 (MV backbone)”. The corrected notation for this should be “INO-4500 (DNA-based vaccine)”.
There was an error in a sentence in the first paragraph of Section 4.1. Measles Virus Platform, published as “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC and is based on the Schwarz strain of the measles virus (MV) [94,95]”, which should be changed to the following version: “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC [94,95]”. The first sentence in the second paragraph of Section 4.1, “In addition to INO-4500, another vaccine candidate has been developed using the Schwarz MV vaccine platform, MV-LASV (V182-001, MeV-NP)”, should be removed.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Murphy, H.; Ly, H. Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines. Vaccines 2022, 10, 1668. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).